Skip to content
    Guidelines & Consensus

    Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026

    Wagle et alCancer

    An American Cancer Society analysis of Surveillance, Epidemiology, and End Results (SEER) population-based registry data from 2000 through 2022 evaluated cancer incidence and 5-year relative survival across 8 Asian American and 3 Native Hawaiian and Pacific Islander (NHPI) ethnic subgroups. The findings demonstrate that combining Asian American and NHPI demographic data into a single aggregated group obscures profound disparities in cancer burden, incidence, and mortality within these heterogeneous populations.
    During the 2018–2022 period, overall cancer incidence varied widely, ranging from a low of 218.3 per 100,000 among Kampuchean individuals to a high of 474.5 per 100,000 among Native Hawaiian individuals. The incidence rate in Native Hawaiian people was 1.5 times higher than the overall aggregated Asian American and NHPI rate of 307.3 per 100,000, primarily driven by high rates of female breast, colorectal, and prostate cancers. In contrast, infection-related malignancies disproportionately affected specific Asian American subgroups; liver cancer incidence was highest in Vietnamese individuals (22.2 per 100,000) and stomach cancer incidence peaked in Korean individuals (17.8 per 100,000), nearly doubling the rates recorded in Native Hawaiian individuals (12.9 and 9.6 per 100,000, respectively). In addition, Native Hawaiian and Samoan women faced marked disparities in uterine corpus cancer, showing 2-fold and 3-fold higher risks, respectively, compared to White women or aggregated Asian American and NHPI populations.
    Disaggregate analysis of 5-year relative survival revealed significant survival gaps across ethnic groups, ranging from 42% in Laotian individuals to 74% in Asian Indian/Pakistani individuals. Site-specific survival variations were pronounced for colorectal cancer (ranging from 43% in Laotians to 72% in Asian Indians/Pakistanis) and prostate cancer (ranging from 63% in Kampucheans to 97% in Japanese individuals). These population-level findings underscore the necessity of collecting and analyzing disaggregated health data to effectively guide targeted cancer prevention, screening, and clinical control measures across distinct Asian American and NHPI communities.

    Key Takeaways

    • Overall cancer incidence among disaggregated groups during 2018–2022 ranged from 218.3 per 100,000 in Kampuchean people to 474.5 per 100,000 in Native Hawaiian people, which was 1.5 times the aggregated Asian American and Native Hawaiian/Pacific Islander population rate of 307.3 per 100,000.
    • Infection-related liver cancer incidence peaked among Vietnamese people (22.2 per 100,000) and stomach cancer among Korean people (17.8 per 100,000), while Native Hawaiian and Samoan women experienced 2-fold and 3-fold higher risks of uterine corpus cancer, respectively, compared to White women or aggregated populations.
    • Five-year relative survival varied widely across ethnic subgroups from 42% in Laotians to 74% in Asian Indians/Pakistanis, with substantial gaps observed for colorectal cancer (43% in Laotians vs. 72% in Asian Indians/Pakistanis) and prostate cancer (63% in Kampucheans vs. 97% in Japanese people).